Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Oragenics Stock Up 2.9 %

Oragenics stock opened at $0.37 on Friday. The firm has a 50 day moving average price of $0.33 and a 200-day moving average price of $0.74. Oragenics has a twelve month low of $0.25 and a twelve month high of $7.74. The company has a market capitalization of $4.46 million, a P/E ratio of -0.05 and a beta of 0.43.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.